NASDAQ:NDRA ENDRA Life Sciences (NDRA) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free NDRA Stock Alerts $1.08 +0.08 (+8.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.03▼$1.0950-Day Range$1.00▼$1.3252-Week Range$0.87▼$3.65Volume101,558 shsAverage Volume125,208 shsMarket Capitalization$11.92 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get ENDRA Life Sciences alerts: Email Address ENDRA Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$9.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector738th out of 947 stocksElectromedical Equipment Industry16th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, ENDRA Life Sciences has a forecasted upside of 733.3% from its current price of $1.08.Amount of Analyst CoverageENDRA Life Sciences has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently increased by 86.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NDRA. Previous Next 1.8 News and Social Media Coverage News SentimentENDRA Life Sciences has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ENDRA Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NDRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 6.03% of the stock of ENDRA Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r About ENDRA Life Sciences Stock (NASDAQ:NDRA)ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Read More NDRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NDRA Stock News HeadlinesMarch 14, 2024 | msn.comNuclera appoints Joseph Bertelsen as Chief Commercial OfficerMarch 6, 2024 | bizjournals.comLife sciences companies need more than just scientistsMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 28, 2024 | msn.comENDRA installs first TAEUS liver system at London hospitalFebruary 27, 2024 | finance.yahoo.comENDRA Life Sciences Installs First TAEUS System in the UKFebruary 27, 2024 | businesswire.comENDRA Life Sciences Installs First TAEUS System in the UKFebruary 23, 2024 | msn.comNew findings suggest life span can be increased by making cells less efficient at producing energyFebruary 21, 2024 | finance.yahoo.comNew ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS SystemMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 21, 2024 | businesswire.comNew ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS SystemFebruary 21, 2024 | investing.comENDRA Life Sciences Inc (NDRA)February 17, 2024 | investing.comENDRA Life Sciences secures new patents for ultrasound techFebruary 15, 2024 | wsj.comENDRA Life Sciences Inc.February 14, 2024 | businesswire.comENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and EuropeFebruary 9, 2024 | msn.comNirma Rs 1,343 crore open offer to buy more stake in Glenmark Life Sciences to start on Feb 15February 6, 2024 | msn.comPanacea Life Sciences Strikes, Rescinds PUR Medical DealFebruary 4, 2024 | markets.businessinsider.comNurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. GrantDecember 10, 2023 | benzinga.comENDRA Life Sciences Stock (NASDAQ:NDRA) Dividends: History, Yield and DatesNovember 29, 2023 | finance.yahoo.comENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System TechnologyNovember 16, 2023 | msn.com$116 Million Life Sciences, Health Care, and Tech Innovation Hub Coming to Jersey CityNovember 15, 2023 | msn.comDallas-based company plans to resurrect prehistoric lifeNovember 15, 2023 | finance.yahoo.comENDRA Life Sciences Inc. (NASDAQ:NDRA) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | benzinga.comENDRA Life Sciences: Q3 Earnings InsightsNovember 14, 2023 | msn.comEndra Life Sciences GAAP EPS of -$0.40 beats by $0.03November 14, 2023 | finance.yahoo.comENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 14, 2023 | msn.comLife science firms may consider regulatory pathways to promote innovations in SEANovember 13, 2023 | benzinga.comEarnings Preview: ENDRA Life SciencesSee More Headlines Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/18/2024Next Earnings (Estimated)3/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:NDRA CUSIPN/A CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+733.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-211.26% Return on Assets-151.72% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio1.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book0.47Miscellaneous Outstanding Shares11,040,000Free Float10,506,000Market Cap$11.92 million OptionableNot Optionable Beta1.04 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Francois Michelon (Age 58)Chairman, President & CEO Comp: $423.59kMr. Michael Thornton Ph.D. (Age 56)Chief Technology Officer Comp: $301.67kDr. Jonathan Behr Ph.D.Co-FounderMs. Irina Pestrikova (Age 37)Senior Director of Finance & Secretary Mr. Steve FreemanHuman Resources LeaderKey CompetitorsNeurAxisNASDAQ:NRXSBioSig TechnologiesNASDAQ:BSGMHelius Medical TechnologiesNASDAQ:HSDTMovanoNASDAQ:MOVEPrecision OpticsNASDAQ:POCIView All CompetitorsInsidersMichael Milos ThorntonBought 15,000 shares on 5/18/2023Total: $24,750.00 ($1.65/share)Anthony DigiandomenicoBought 83,333 shares on 5/2/2023Total: $99,999.60 ($1.20/share)View All Insider Transactions NDRA Stock Analysis - Frequently Asked Questions Should I buy or sell ENDRA Life Sciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NDRA shares. View NDRA analyst ratings or view top-rated stocks. What is ENDRA Life Sciences' stock price target for 2024? 1 brokerages have issued 12 month price targets for ENDRA Life Sciences' shares. Their NDRA share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for NDRA or view top-rated stocks among Wall Street analysts. How have NDRA shares performed in 2024? ENDRA Life Sciences' stock was trading at $2.12 at the beginning of the year. Since then, NDRA stock has decreased by 49.1% and is now trading at $1.08. View the best growth stocks for 2024 here. Are investors shorting ENDRA Life Sciences? ENDRA Life Sciences saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 54,700 shares, an increase of 86.1% from the February 14th total of 29,400 shares. Based on an average daily trading volume, of 133,400 shares, the short-interest ratio is presently 0.4 days. Approximately 0.5% of the shares of the stock are short sold. View ENDRA Life Sciences' Short Interest. When is ENDRA Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 19th 2024. View our NDRA earnings forecast. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. During the same quarter in the previous year, the firm earned ($0.15) EPS. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), electroCore (ECOR) and Genocea Biosciences (GNCA). When did ENDRA Life Sciences IPO? (NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO. How do I buy shares of ENDRA Life Sciences? Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NDRA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.